Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Magnus Ingelman-Sundberg

Showing results (51-60 of 284) with videos related to

Pageof 29
Sort By:
Glia|November 23, 2006
Glutamate activates c-fos in glial cells via a novel mechanism involving the glutamate receptor subtype mGlu5 and the transcriptional repressor DREAMYlva Edling, Magnus Ingelman-Sundberg, Anastasia Simi
Biochemical and Biophysical Research Communications|December 28, 2005
3'-UTR polymorphism in the human CYP2A6 gene affects mRNA stability and enzyme expressionJue Wang, Mariá Pitarque, Magnus Ingelman-Sundberg
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 3, 2007
Characterization of the novel defective CYP2C9*24 alleleDarja Herman, Vita Dolzan, Magnus Ingelman-Sundberg
Annual Review of Medicine|January 18, 2006
Pharmacogenomics and individualized drug therapyMichel Eichelbaum, Magnus Ingelman-Sundberg, William E Evans
Clinical Pharmacology and Therapeutics|September 16, 2022
Response to Rowland et al. and Achour et alChris S Pridgeon, Inger Johansson, Magnus Ingelman-Sundberg
Pharmacogenomics|December 16, 2014
Polymorphic expression of CYP2C19 and CYP2D6 in the developing and adult human brain causing variability in cognition, risk for depression and suicide: the search for the endogenous substratesMagnus Ingelman-Sundberg, Anna Persson, Marin M Jukic
The AAPS Journal|November 29, 2017
Pharmacogenomic Biomarkers for Improved Drug Therapy-Recent Progress and Future DevelopmentsVolker M Lauschke, Lili Milani, Magnus Ingelman-Sundberg
Annual Review of Pharmacology and Toxicology|October 15, 2017
Pharmacoepigenetics and Toxicoepigenetics: Novel Mechanistic Insights and Therapeutic OpportunitiesVolker M Lauschke, Isabel Barragan, Magnus Ingelman-Sundberg
International Journal of Molecular Sciences|August 7, 2021
CYP2E1 in Alcoholic and Non-Alcoholic Liver Injury. Roles of ROS, Reactive Intermediates and Lipid OverloadRiina Harjumäki, Chris S Pridgeon, Magnus Ingelman-Sundberg
Trends in Pharmacological Sciences|June 20, 2017
Pitfalls and Opportunities for Epigenomic Analyses Focused on Disease Diagnosis, Prognosis, and TherapyVolker M Lauschke, Maxim Ivanov, Magnus Ingelman-Sundberg
Pageof 29

Showing results (51-60 of 284) with videos related to

Sort By:
Pageof 29
Glia|November 23, 2006
Glutamate activates c-fos in glial cells via a novel mechanism involving the glutamate receptor subtype mGlu5 and the transcriptional repressor DREAMYlva Edling, Magnus Ingelman-Sundberg, Anastasia Simi
Biochemical and Biophysical Research Communications|December 28, 2005
3'-UTR polymorphism in the human CYP2A6 gene affects mRNA stability and enzyme expressionJue Wang, Mariá Pitarque, Magnus Ingelman-Sundberg
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 3, 2007
Characterization of the novel defective CYP2C9*24 alleleDarja Herman, Vita Dolzan, Magnus Ingelman-Sundberg
Annual Review of Medicine|January 18, 2006
Pharmacogenomics and individualized drug therapyMichel Eichelbaum, Magnus Ingelman-Sundberg, William E Evans
Clinical Pharmacology and Therapeutics|September 16, 2022
Response to Rowland et al. and Achour et alChris S Pridgeon, Inger Johansson, Magnus Ingelman-Sundberg
Pharmacogenomics|December 16, 2014
Polymorphic expression of CYP2C19 and CYP2D6 in the developing and adult human brain causing variability in cognition, risk for depression and suicide: the search for the endogenous substratesMagnus Ingelman-Sundberg, Anna Persson, Marin M Jukic
The AAPS Journal|November 29, 2017
Pharmacogenomic Biomarkers for Improved Drug Therapy-Recent Progress and Future DevelopmentsVolker M Lauschke, Lili Milani, Magnus Ingelman-Sundberg
Annual Review of Pharmacology and Toxicology|October 15, 2017
Pharmacoepigenetics and Toxicoepigenetics: Novel Mechanistic Insights and Therapeutic OpportunitiesVolker M Lauschke, Isabel Barragan, Magnus Ingelman-Sundberg
International Journal of Molecular Sciences|August 7, 2021
CYP2E1 in Alcoholic and Non-Alcoholic Liver Injury. Roles of ROS, Reactive Intermediates and Lipid OverloadRiina Harjumäki, Chris S Pridgeon, Magnus Ingelman-Sundberg
Trends in Pharmacological Sciences|June 20, 2017
Pitfalls and Opportunities for Epigenomic Analyses Focused on Disease Diagnosis, Prognosis, and TherapyVolker M Lauschke, Maxim Ivanov, Magnus Ingelman-Sundberg
Pageof 29